Your account is not claimed yet. You can sign up with ORCID to claim your account.

Xianquan Zhan

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2023
Publications (10 Years): 30

Top Venues

The EPMA journal

Oxidative medicine and cellular longevity

Electrophoresis

Journal of mass spectrometry : JMS

Central South University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Central South University Feb 1o 2012

China

Professor :: Xiangya Hospital

Publications

Lamei Yang, Chunling Li, Tao Song, Xianquan Zhan
Growth hormone proteoformics atlas created to promote predictive, preventive, and personalized approach in overall management of pituitary neuroendocrine tumors. The EPMA journal 14 (3) (2023)
Hua Yang, Na Li, Liang Chen, Lei Zhou, Yuanchen Zhou, Jixiang Liu, Wenshuang Jia, Ruofei Chen, Junwen Su, Lamei Yang, Xiaoxia Gong, Xianquan Zhan
Ubiquitinomics revealed disease- and stage-specific patterns relevant for the 3PM approach in human sigmoid colon cancers. The EPMA journal 14 (3) (2023)
Yuping Zhang, Na Li, Lamei Yang, Wenshuang Jia, Zhijun Li, Qianwen Shao, Xianquan Zhan
Quantitative phosphoproteomics reveals molecular pathway network alterations in human early-stage primary hepatic carcinomas: potential for 3P medical approach. The EPMA journal 14 (3) (2023)
Nadia M Hamdy, Fatma H Shaker, Xianquan Zhan, Emad B Basalious
Tangled quest of post-COVID-19 infection-caused neuropathology and what 3P nano-bio-medicine can solve? The EPMA journal 13 (2) (2022)
Na Li, Xianquan Zhan
Machine Learning Identifies Pan-Cancer Landscape of Nrf2 Oxidative Stress Response Pathway-Related Genes. Oxidative medicine and cellular longevity 2022 (2022)
Guodong Zhang, Zhengdan Wang, Pingping Song, Xianquan Zhan
DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine. The EPMA journal 13 (4) (2022)
Liang Shen, Xianquan Zhan
Mitochondrial Dysfunction Pathway Alterations Offer Potential Biomarkers and Therapeutic Targets for Ovarian Cancer. Oxidative medicine and cellular longevity 2022 (2022)
Zhen Ye, Aiying Bing, Shulian Zhao, Shuying Yi, Xianquan Zhan
Comprehensive analysis of spliceosome genes and their mutants across 27 cancer types in 9070 patients: clinically relevant outcomes in the context of 3P medicine. The EPMA journal 13 (2) (2022)
Guodong Zhang, Zhengdan Wang, Pingping Song, Xianquan Zhan
DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine. The EPMA journal 13 (4) (2022)
Siqi Wen, Chunling Li, Xianquan Zhan
Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine. The EPMA journal 13 (1) (2022)
Xianquan Zhan, Peter R Jungblut
The comparison between 2DE-MS and bottom-up LC-MS demands high-end techniques for both technologies. Electrophoresis 43 (11) (2022)
Zhen Ye, Huanhuan Zhang, Fanhua Kong, Jing Lan, Shuying Yi, Wenshuang Jia, Shu Zheng, Yuna Guo, Xianquan Zhan
Comprehensive Analysis of Alteration Landscape and Its Clinical Significance of Mitochondrial Energy Metabolism Pathway-Related Genes in Lung Cancers. Oxidative medicine and cellular longevity 2021 (2021)
Biao Li, Xiaowei Wang, Chenguang Yang, Siqi Wen, Jiajia Li, Na Li, Ying Long, Yun Mu, Jianping Liu, Qin Liu, Xuejun Li, Dominic M Desiderio, Xianquan Zhan
Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches. The EPMA journal 12 (1) (2021)
Na Li, Nannan Li, Siqi Wen, Biao Li, Yaying Zhang, Qing Liu, Shu Zheng, Jingru Yang, Liang Shen, Ligang Xing, Xianquan Zhan
HSP60 Regulates Lipid Metabolism in Human Ovarian Cancer. Oxidative medicine and cellular longevity 2021 (2021)
Na Li, Xianquan Zhan
Integrated genomic analysis of proteasome alterations across 11,057 patients with 33 cancer types: clinically relevant outcomes in framework of 3P medicine. The EPMA journal 12 (4) (2021)
Na Li, Huanni Li, Ya Wang, Lanqin Cao, Xianquan Zhan
Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine. The EPMA journal 11 (4) (2020)
Na Li, Jiajia Li, Dominic M Desiderio, Xianquan Zhan
SILAC quantitative proteomics analysis of ivermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells. Journal of mass spectrometry : JMS 56 (1) (2020)
Na Li, Xianquan Zhan
Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. The EPMA journal 11 (2) (2020)
Dan Liu, Jiajia Li, Na Li, Miaolong Lu, Siqi Wen, Xianquan Zhan
Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas. The EPMA journal 11 (3) (2020)
Na Li, Xianquan Zhan
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. The EPMA journal 11 (3) (2020)
Na Li, Lingfeng Zhao, Xianquan Zhan
Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Journal of cellular physiology 236 (4) (2020)
Miaolong Lu, Wei Chen, Wei Zhuang, Xianquan Zhan
Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas. The EPMA journal 11 (1) (2020)
Ya Wang, Tingting Cheng, Miaolong Lu, Yun Mu, Biao Li, Xuejun Li, Xianquan Zhan
TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas. The EPMA journal 10 (4) (2019)
Na Li, Xianquan Zhan
Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics. The EPMA journal 10 (2) (2019)
Na Li, Xianquan Zhan
Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer. The EPMA journal 10 (3) (2019)
Xianquan Zhan, Biao Li, Xiaohan Zhan, Hartmut Schlüter, Peter R Jungblut, Jens R Coorssen
Innovating the Concept and Practice of Two-Dimensional Gel Electrophoresis in the Analysis of Proteomes at the Proteoform Level. Proteomes 7 (4) (2019)
Shehua Qian, Olga Golubnitschaja, Xianquan Zhan
Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. The EPMA journal 10 (4) (2019)
Xianquan Zhan, Haiyan Yang, Fang Peng, Jianglin Li, Yun Mu, Ying Long, Tingting Cheng, Yuda Huang, Zhao Li, Miaolong Lu, Na Li, Maoyu Li, Jianping Liu, Peter R Jungblut
How many proteins can be identified in a 2DE gel spot within an analysis of a complex human cancer tissue proteome? Electrophoresis 39 (7) (2018)
Miaolong Lu, Xianquan Zhan
The crucial role of multiomic approach in cancer research and clinically relevant outcomes. The EPMA journal 9 (1) (2018)
Tianyao Guo, Xiaowei Wang, Maoyu Li, Haiyan Yang, Ling Li, Fang Peng, Xianquan Zhan
Identification of Glioblastoma Phosphotyrosine-Containing Proteins with Two-Dimensional Western Blotting and Tandem Mass Spectrometry. BioMed research international 2015 (2015)

Xianquan Zhan.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xianquan Zhan